- Home
- FGII vs ABEO Comparison
FGII vs ABEO Comparison
Compare FGII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGII | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.4M | 320.3M |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FGII | ABEO |
|---|---|---|
| Price | $9.94 | $6.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 12.5K | ★ 1.3M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.86 | $4.00 |
| 52 Week High | $9.99 | $7.54 |
Technical Indicators
Market Signals| Indicator | FGII | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 68.60 |
| Support Level | N/A | $5.19 |
| Resistance Level | $9.99 | N/A |
| Average True Range (ATR) | 0.01 | 0.25 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 16.67 | 97.81 |
Price Performance
Historical ComparisonAbout FGII FG Imperii Acquisition Corp. Class A Ordinary Shares
FG Imperii Acquisition Corp is a blank check company incorporated in the Cayman Islands. The company was formed for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.